Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

By Nigel Rawson and John Adams The Patented Medicine Prices Review Board (PMPRB), Canada’s federal gatekeeper under the ...

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...

Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

Never Get Busted documents a decorated narcotics officer in Texas turn toward libertarianism as he aims to expose police misconduct and helps drug users slip under the radar. The docuseries, more than ...

Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration ...

There were unforgiveable shortcomings in management, which included critical information not reaching senior officials as ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.